Teva secures FDA approval for new formulation of COPAXONE

Israel-based Teva Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its supplemental new drug application (sNDA) for three-times-a-week COPAXONE 40mg/mL, a new dose of COPAXONE (glatiramer acetate injection) indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS).

CLICK ON TITLE BELOW

Teva secures FDA approval for new formulation of COPAXONE 


88THBGU6YBFQ